TABLE 13: Treatment - teletherapy

% of Cases treated with Teletherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales
All invasive xnmsc 19.6% 18.5% 19.5% 15.6% - 20.4%
All xnmsc 0-24 20.1% 11.9% 12.0% 10.3% - 13.4%
All xnmsc 25-59 22.2% 22.9% 21.7% 21.1% - 26.0%
All xnmsc 60-79 21.9% 19.9% 21.8% 16.0% - 22.0%
All xnmsc 80+ 12.2% 10.6% 11.8% 8.4% - 11.6%
Haematology 10.2% 8.4% 9.2% 7.0% - 8.9%
Head and Neck 60.5% 52.0% 59.1% 35.5% - 61.3%
Lower GI 13.4% 12.0% 12.8% 10.7% - 12.5%
Upper GI 20.9% 17.6% 18.9% 11.9% - 22.0%
HPB 4.0% 2.0% 2.2% 1.1% - 2.8%
Trachea, Bronchus & Lung 26.1% 25.0% 25.6% 24.3% - 25.1%
Melanoma of skin 2.7% 0.5% 0.7% 0.0% - 0.8%
Breast 37.7% 38.1% 37.1% 36.4% - 40.8%
Prostate 46.0% 40.3% 39.4% 33.4% - 48.1%
Cervix 11.2% 11.0% 8.9% 6.1% - 17.8%
Other Female Genitals 19.2% 12.3% 19.0% 3.7% - 14.1%
Kidney 7.5% 4.7% 4.9% 3.9% - 5.4%
Bladder 19.8% 18.0% 16.7% 15.2% - 22.2%
Brain and CNS 49.8% 41.4% 46.6% 30.6% - 47.1%
Thyroid & other endocrine glands 15.0% 13.2% 7.2% 5.1% - 27.2%
CUP 15.3% 11.7% 11.5% 9.8% - 13.9%
Other invasive cancer 13.5% 9.7% 10.7% 7.1% - 11.2%
Breast in situ 34.8% 32.1% 32.2% 32.8% - 31.3%
Cervix in situ 1.5% 0.0% 0.0% 0.0% - 0.0%
Other tumours 1.8% 0.7% 1.0% 0.0% - 0.9%
Non-Melanoma Skin Cancer 2.1% 1.1% 1.9% 0.4% - 1.1%